Drug Profile
Research programme: anti-cancer therapeutics - Zestagen
Alternative Names: mAb 4C5; ZSG 101; ZSG 102; ZSG 103Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Hellenic Pasteur Institute
- Developer Hellenic Pasteur Institute; Zestagen
- Class Monoclonal antibodies
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Malignant melanoma; Non-small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for research development in Non-small-cell-lung-cancer in Switzerland (Injection)
- 28 Jun 2018 No recent reports of development identified for research development in Malignant-melanoma in Greece (Intraperitoneal, Injection)
- 28 Jun 2018 No recent reports of development identified for research development in Triple negative Breast-cancer in Greece (Injection)